Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Haemophilia Drug Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Blood-derived Coagulation Factor
1.2.3 Recombinant Coagulation Factor
1.3 Market by Application
1.3.1 Global Haemophilia Drug Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Haemophilia A
1.3.3 Haemophilia B
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Haemophilia Drug Market Perspective (2024-2034)
2.2 Haemophilia Drug Growth Trends by Region
2.2.1 Global Haemophilia Drug Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Haemophilia Drug Historic Market Size by Region (2024-2024)
2.2.3 Haemophilia Drug Forecasted Market Size by Region (2024-2034)
2.3 Haemophilia Drug Market Dynamics
2.3.1 Haemophilia Drug Industry Trends
2.3.2 Haemophilia Drug Market Drivers
2.3.3 Haemophilia Drug Market Challenges
2.3.4 Haemophilia Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Haemophilia Drug Players by Revenue
3.1.1 Global Top Haemophilia Drug Players by Revenue (2024-2024)
3.1.2 Global Haemophilia Drug Revenue Market Share by Players (2024-2024)
3.2 Global Haemophilia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Haemophilia Drug Revenue
3.4 Global Haemophilia Drug Market Concentration Ratio
3.4.1 Global Haemophilia Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Haemophilia Drug Revenue in 2022
3.5 Haemophilia Drug Key Players Head office and Area Served
3.6 Key Players Haemophilia Drug Product Solution and Service
3.7 Date of Enter into Haemophilia Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Haemophilia Drug Breakdown Data by Type
4.1 Global Haemophilia Drug Historic Market Size by Type (2024-2024)
4.2 Global Haemophilia Drug Forecasted Market Size by Type (2024-2034)
5 Haemophilia Drug Breakdown Data by Application
5.1 Global Haemophilia Drug Historic Market Size by Application (2024-2024)
5.2 Global Haemophilia Drug Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Haemophilia Drug Market Size (2024-2034)
6.2 North America Haemophilia Drug Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Haemophilia Drug Market Size by Country (2024-2024)
6.4 North America Haemophilia Drug Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Haemophilia Drug Market Size (2024-2034)
7.2 Europe Haemophilia Drug Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Haemophilia Drug Market Size by Country (2024-2024)
7.4 Europe Haemophilia Drug Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Haemophilia Drug Market Size (2024-2034)
8.2 Asia-Pacific Haemophilia Drug Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Haemophilia Drug Market Size by Region (2024-2024)
8.4 Asia-Pacific Haemophilia Drug Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Haemophilia Drug Market Size (2024-2034)
9.2 Latin America Haemophilia Drug Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Haemophilia Drug Market Size by Country (2024-2024)
9.4 Latin America Haemophilia Drug Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Haemophilia Drug Market Size (2024-2034)
10.2 Middle East & Africa Haemophilia Drug Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Haemophilia Drug Market Size by Country (2024-2024)
10.4 Middle East & Africa Haemophilia Drug Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Shire (Baxter)
11.1.1 Shire (Baxter) Company Detail
11.1.2 Shire (Baxter) Business Overview
11.1.3 Shire (Baxter) Haemophilia Drug Introduction
11.1.4 Shire (Baxter) Revenue in Haemophilia Drug Business (2024-2024)
11.1.5 Shire (Baxter) Recent Development
11.2 CSL
11.2.1 CSL Company Detail
11.2.2 CSL Business Overview
11.2.3 CSL Haemophilia Drug Introduction
11.2.4 CSL Revenue in Haemophilia Drug Business (2024-2024)
11.2.5 CSL Recent Development
11.3 Grifols
11.3.1 Grifols Company Detail
11.3.2 Grifols Business Overview
11.3.3 Grifols Haemophilia Drug Introduction
11.3.4 Grifols Revenue in Haemophilia Drug Business (2024-2024)
11.3.5 Grifols Recent Development
11.4 Biogen
11.4.1 Biogen Company Detail
11.4.2 Biogen Business Overview
11.4.3 Biogen Haemophilia Drug Introduction
11.4.4 Biogen Revenue in Haemophilia Drug Business (2024-2024)
11.4.5 Biogen Recent Development
11.5 Octapharma
11.5.1 Octapharma Company Detail
11.5.2 Octapharma Business Overview
11.5.3 Octapharma Haemophilia Drug Introduction
11.5.4 Octapharma Revenue in Haemophilia Drug Business (2024-2024)
11.5.5 Octapharma Recent Development
11.6 Kedrion
11.6.1 Kedrion Company Detail
11.6.2 Kedrion Business Overview
11.6.3 Kedrion Haemophilia Drug Introduction
11.6.4 Kedrion Revenue in Haemophilia Drug Business (2024-2024)
11.6.5 Kedrion Recent Development
11.7 BPL
11.7.1 BPL Company Detail
11.7.2 BPL Business Overview
11.7.3 BPL Haemophilia Drug Introduction
11.7.4 BPL Revenue in Haemophilia Drug Business (2024-2024)
11.7.5 BPL Recent Development
11.8 Bayer
11.8.1 Bayer Company Detail
11.8.2 Bayer Business Overview
11.8.3 Bayer Haemophilia Drug Introduction
11.8.4 Bayer Revenue in Haemophilia Drug Business (2024-2024)
11.8.5 Bayer Recent Development
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Detail
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Haemophilia Drug Introduction
11.9.4 Novo Nordisk Revenue in Haemophilia Drug Business (2024-2024)
11.9.5 Novo Nordisk Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Haemophilia Drug Introduction
11.10.4 Pfizer Revenue in Haemophilia Drug Business (2024-2024)
11.10.5 Pfizer Recent Development
11.11 Roche
11.11.1 Roche Company Detail
11.11.2 Roche Business Overview
11.11.3 Roche Haemophilia Drug Introduction
11.11.4 Roche Revenue in Haemophilia Drug Business (2024-2024)
11.11.5 Roche Recent Development
11.12 Baxter
11.12.1 Baxter Company Detail
11.12.2 Baxter Business Overview
11.12.3 Baxter Haemophilia Drug Introduction
11.12.4 Baxter Revenue in Haemophilia Drug Business (2024-2024)
11.12.5 Baxter Recent Development
11.13 Sinopharm
11.13.1 Sinopharm Company Detail
11.13.2 Sinopharm Business Overview
11.13.3 Sinopharm Haemophilia Drug Introduction
11.13.4 Sinopharm Revenue in Haemophilia Drug Business (2024-2024)
11.13.5 Sinopharm Recent Development
11.14 Shanghai Raas Blood Products
11.14.1 Shanghai Raas Blood Products Company Detail
11.14.2 Shanghai Raas Blood Products Business Overview
11.14.3 Shanghai Raas Blood Products Haemophilia Drug Introduction
11.14.4 Shanghai Raas Blood Products Revenue in Haemophilia Drug Business (2024-2024)
11.14.5 Shanghai Raas Blood Products Recent Development
11.15 China Biologic Products
11.15.1 China Biologic Products Company Detail
11.15.2 China Biologic Products Business Overview
11.15.3 China Biologic Products Haemophilia Drug Introduction
11.15.4 China Biologic Products Revenue in Haemophilia Drug Business (2024-2024)
11.15.5 China Biologic Products Recent Development
11.16 Hualan Bio
11.16.1 Hualan Bio Company Detail
11.16.2 Hualan Bio Business Overview
11.16.3 Hualan Bio Haemophilia Drug Introduction
11.16.4 Hualan Bio Revenue in Haemophilia Drug Business (2024-2024)
11.16.5 Hualan Bio Recent Development
11.17 CGE Healthcare
11.17.1 CGE Healthcare Company Detail
11.17.2 CGE Healthcare Business Overview
11.17.3 CGE Healthcare Haemophilia Drug Introduction
11.17.4 CGE Healthcare Revenue in Haemophilia Drug Business (2024-2024)
11.17.5 CGE Healthcare Recent Development
11.18 Sinocelltech Group
11.18.1 Sinocelltech Group Company Detail
11.18.2 Sinocelltech Group Business Overview
11.18.3 Sinocelltech Group Haemophilia Drug Introduction
11.18.4 Sinocelltech Group Revenue in Haemophilia Drug Business (2024-2024)
11.18.5 Sinocelltech Group Recent Development
11.19 Shanxi Kangbao Biological
11.19.1 Shanxi Kangbao Biological Company Detail
11.19.2 Shanxi Kangbao Biological Business Overview
11.19.3 Shanxi Kangbao Biological Haemophilia Drug Introduction
11.19.4 Shanxi Kangbao Biological Revenue in Haemophilia Drug Business (2024-2024)
11.19.5 Shanxi Kangbao Biological Recent Development
11.20 CTTQ
11.20.1 CTTQ Company Detail
11.20.2 CTTQ Business Overview
11.20.3 CTTQ Haemophilia Drug Introduction
11.20.4 CTTQ Revenue in Haemophilia Drug Business (2024-2024)
11.20.5 CTTQ Recent Development
11.21 GC Biopharma
11.21.1 GC Biopharma Company Detail
11.21.2 GC Biopharma Business Overview
11.21.3 GC Biopharma Haemophilia Drug Introduction
11.21.4 GC Biopharma Revenue in Haemophilia Drug Business (2024-2024)
11.21.5 GC Biopharma Recent Development
11.22 Belief BioMed
11.22.1 Belief BioMed Company Detail
11.22.2 Belief BioMed Business Overview
11.22.3 Belief BioMed Haemophilia Drug Introduction
11.22.4 Belief BioMed Revenue in Haemophilia Drug Business (2024-2024)
11.22.5 Belief BioMed Recent Development
11.23 AryoGen Pharmed
11.23.1 AryoGen Pharmed Company Detail
11.23.2 AryoGen Pharmed Business Overview
11.23.3 AryoGen Pharmed Haemophilia Drug Introduction
11.23.4 AryoGen Pharmed Revenue in Haemophilia Drug Business (2024-2024)
11.23.5 AryoGen Pharmed Recent Development
11.24 GENERIUM
11.24.1 GENERIUM Company Detail
11.24.2 GENERIUM Business Overview
11.24.3 GENERIUM Haemophilia Drug Introduction
11.24.4 GENERIUM Revenue in Haemophilia Drug Business (2024-2024)
11.24.5 GENERIUM Recent Development
11.25 LFB SA
11.25.1 LFB SA Company Detail
11.25.2 LFB SA Business Overview
11.25.3 LFB SA Haemophilia Drug Introduction
11.25.4 LFB SA Revenue in Haemophilia Drug Business (2024-2024)
11.25.5 LFB SA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Haemophilia Drug Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Blood-derived Coagulation Factor
Table 3. Key Players of Recombinant Coagulation Factor
Table 4. Global Haemophilia Drug Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 5. Global Haemophilia Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 6. Global Haemophilia Drug Market Size by Region (2024-2024) & (US$ Million)
Table 7. Global Haemophilia Drug Market Share by Region (2024-2024)
Table 8. Global Haemophilia Drug Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 9. Global Haemophilia Drug Market Share by Region (2024-2034)
Table 10. Haemophilia Drug Market Trends
Table 11. Haemophilia Drug Market Drivers
Table 12. Haemophilia Drug Market Challenges
Table 13. Haemophilia Drug Market Restraints
Table 14. Global Haemophilia Drug Revenue by Players (2024-2024) & (US$ Million)
Table 15. Global Haemophilia Drug Market Share by Players (2024-2024)
Table 16. Global Top Haemophilia Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Haemophilia Drug as of 2022)
Table 17. Ranking of Global Top Haemophilia Drug Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Haemophilia Drug Revenue (CR5 and HHI) & (2024-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Haemophilia Drug Product Solution and Service
Table 21. Date of Enter into Haemophilia Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Haemophilia Drug Market Size by Type (2024-2024) & (US$ Million)
Table 24. Global Haemophilia Drug Revenue Market Share by Type (2024-2024)
Table 25. Global Haemophilia Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Haemophilia Drug Revenue Market Share by Type (2024-2034)
Table 27. Global Haemophilia Drug Market Size by Application (2024-2024) & (US$ Million)
Table 28. Global Haemophilia Drug Revenue Market Share by Application (2024-2024)
Table 29. Global Haemophilia Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Haemophilia Drug Revenue Market Share by Application (2024-2034)
Table 31. North America Haemophilia Drug Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 32. North America Haemophilia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 33. North America Haemophilia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 34. Europe Haemophilia Drug Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 35. Europe Haemophilia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 36. Europe Haemophilia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 37. Asia-Pacific Haemophilia Drug Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 38. Asia-Pacific Haemophilia Drug Market Size by Region (2024-2024) & (US$ Million)
Table 39. Asia-Pacific Haemophilia Drug Market Size by Region (2024-2034) & (US$ Million)
Table 40. Latin America Haemophilia Drug Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 41. Latin America Haemophilia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 42. Latin America Haemophilia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 43. Middle East & Africa Haemophilia Drug Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 44. Middle East & Africa Haemophilia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 45. Middle East & Africa Haemophilia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 46. Shire (Baxter) Company Detail
Table 47. Shire (Baxter) Business Overview
Table 48. Shire (Baxter) Haemophilia Drug Product
Table 49. Shire (Baxter) Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 50. Shire (Baxter) Recent Development
Table 51. CSL Company Detail
Table 52. CSL Business Overview
Table 53. CSL Haemophilia Drug Product
Table 54. CSL Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 55. CSL Recent Development
Table 56. Grifols Company Detail
Table 57. Grifols Business Overview
Table 58. Grifols Haemophilia Drug Product
Table 59. Grifols Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 60. Grifols Recent Development
Table 61. Biogen Company Detail
Table 62. Biogen Business Overview
Table 63. Biogen Haemophilia Drug Product
Table 64. Biogen Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 65. Biogen Recent Development
Table 66. Octapharma Company Detail
Table 67. Octapharma Business Overview
Table 68. Octapharma Haemophilia Drug Product
Table 69. Octapharma Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 70. Octapharma Recent Development
Table 71. Kedrion Company Detail
Table 72. Kedrion Business Overview
Table 73. Kedrion Haemophilia Drug Product
Table 74. Kedrion Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 75. Kedrion Recent Development
Table 76. BPL Company Detail
Table 77. BPL Business Overview
Table 78. BPL Haemophilia Drug Product
Table 79. BPL Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 80. BPL Recent Development
Table 81. Bayer Company Detail
Table 82. Bayer Business Overview
Table 83. Bayer Haemophilia Drug Product
Table 84. Bayer Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 85. Bayer Recent Development
Table 86. Novo Nordisk Company Detail
Table 87. Novo Nordisk Business Overview
Table 88. Novo Nordisk Haemophilia Drug Product
Table 89. Novo Nordisk Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 90. Novo Nordisk Recent Development
Table 91. Pfizer Company Detail
Table 92. Pfizer Business Overview
Table 93. Pfizer Haemophilia Drug Product
Table 94. Pfizer Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 95. Pfizer Recent Development
Table 96. Roche Company Detail
Table 97. Roche Business Overview
Table 98. Roche Haemophilia Drug Product
Table 99. Roche Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 100. Roche Recent Development
Table 101. Baxter Company Detail
Table 102. Baxter Business Overview
Table 103. Baxter Haemophilia Drug Product
Table 104. Baxter Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 105. Baxter Recent Development
Table 106. Sinopharm Company Detail
Table 107. Sinopharm Business Overview
Table 108. Sinopharm Haemophilia Drug Product
Table 109. Sinopharm Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 110. Sinopharm Recent Development
Table 111. Shanghai Raas Blood Products Company Detail
Table 112. Shanghai Raas Blood Products Business Overview
Table 113. Shanghai Raas Blood Products Haemophilia Drug Product
Table 114. Shanghai Raas Blood Products Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 115. Shanghai Raas Blood Products Recent Development
Table 116. China Biologic Products Company Detail
Table 117. China Biologic Products Business Overview
Table 118. China Biologic Products Haemophilia Drug Product
Table 119. China Biologic Products Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 120. China Biologic Products Recent Development
Table 121. Hualan Bio Company Detail
Table 122. Hualan Bio Business Overview
Table 123. Hualan Bio Haemophilia Drug Product
Table 124. Hualan Bio Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 125. Hualan Bio Recent Development
Table 126. CGE Healthcare Company Detail
Table 127. CGE Healthcare Business Overview
Table 128. CGE Healthcare Haemophilia Drug Product
Table 129. CGE Healthcare Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 130. CGE Healthcare Recent Development
Table 131. Sinocelltech Group Company Detail
Table 132. Sinocelltech Group Business Overview
Table 133. Sinocelltech Group Haemophilia Drug Product
Table 134. Sinocelltech Group Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 135. Sinocelltech Group Recent Development
Table 136. Shanxi Kangbao Biological Company Detail
Table 137. Shanxi Kangbao Biological Business Overview
Table 138. Shanxi Kangbao Biological Haemophilia Drug Product
Table 139. Shanxi Kangbao Biological Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 140. Shanxi Kangbao Biological Recent Development
Table 141. CTTQ Company Detail
Table 142. CTTQ Business Overview
Table 143. CTTQ Haemophilia Drug Product
Table 144. CTTQ Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 145. CTTQ Recent Development
Table 146. GC Biopharma Company Detail
Table 147. GC Biopharma Business Overview
Table 148. GC Biopharma Haemophilia Drug Product
Table 149. GC Biopharma Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 150. GC Biopharma Recent Development
Table 151. Belief BioMed Company Detail
Table 152. Belief BioMed Business Overview
Table 153. Belief BioMed Haemophilia Drug Product
Table 154. Belief BioMed Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 155. Belief BioMed Recent Development
Table 156. AryoGen Pharmed Company Detail
Table 157. AryoGen Pharmed Business Overview
Table 158. AryoGen Pharmed Haemophilia Drug Product
Table 159. AryoGen Pharmed Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 160. AryoGen Pharmed Recent Development
Table 161. GENERIUM Company Detail
Table 162. GENERIUM Business Overview
Table 163. GENERIUM Haemophilia Drug Product
Table 164. GENERIUM Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 165. GENERIUM Recent Development
Table 166. LFB SA Company Detail
Table 167. LFB SA Business Overview
Table 168. LFB SA Haemophilia Drug Product
Table 169. LFB SA Revenue in Haemophilia Drug Business (2024-2024) & (US$ Million)
Table 170. LFB SA Recent Development
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Haemophilia Drug Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Haemophilia Drug Market Share by Type: 2022 VS 2034
Figure 3. Blood-derived Coagulation Factor Features
Figure 4. Recombinant Coagulation Factor Features
Figure 5. Global Haemophilia Drug Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 6. Global Haemophilia Drug Market Share by Application: 2022 VS 2034
Figure 7. Haemophilia A Case Studies
Figure 8. Haemophilia B Case Studies
Figure 9. Others Case Studies
Figure 10. Haemophilia Drug Report Years Considered
Figure 11. Global Haemophilia Drug Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 12. Global Haemophilia Drug Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 13. Global Haemophilia Drug Market Share by Region: 2022 VS 2034
Figure 14. Global Haemophilia Drug Market Share by Players in 2022
Figure 15. Global Top Haemophilia Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Haemophilia Drug as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Haemophilia Drug Revenue in 2022
Figure 17. North America Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 18. North America Haemophilia Drug Market Share by Country (2024-2034)
Figure 19. United States Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 20. Canada Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 21. Europe Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 22. Europe Haemophilia Drug Market Share by Country (2024-2034)
Figure 23. Germany Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 24. France Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. U.K. Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. Italy Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. Russia Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. Nordic Countries Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. Asia-Pacific Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Asia-Pacific Haemophilia Drug Market Share by Region (2024-2034)
Figure 31. China Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 32. Japan Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. South Korea Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. Southeast Asia Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. India Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. Australia Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. Latin America Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. Latin America Haemophilia Drug Market Share by Country (2024-2034)
Figure 39. Mexico Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 40. Brazil Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Middle East & Africa Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Middle East & Africa Haemophilia Drug Market Share by Country (2024-2034)
Figure 43. Turkey Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 44. Saudi Arabia Haemophilia Drug Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Shire (Baxter) Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 46. CSL Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 47. Grifols Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 48. Biogen Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 49. Octapharma Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 50. Kedrion Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 51. BPL Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 52. Bayer Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 53. Novo Nordisk Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 54. Pfizer Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 55. Roche Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 56. Baxter Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 57. Sinopharm Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 58. Shanghai Raas Blood Products Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 59. China Biologic Products Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 60. Hualan Bio Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 61. CGE Healthcare Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 62. Sinocelltech Group Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 63. Shanxi Kangbao Biological Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 64. CTTQ Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 65. GC Biopharma Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 66. Belief BioMed Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 67. AryoGen Pharmed Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 68. GENERIUM Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 69. LFB SA Revenue Growth Rate in Haemophilia Drug Business (2024-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed